Compare Direxion NASDAQ 100 Equal Weighted Index Shares (QQQE) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Direxion NASDAQ 100 Equal Weighted Index Shares vs TG Therapeutics Inc — how do they compare? Direxion NASDAQ 100 Equal Weighted Index Shares trades at $121.85 (market cap $1.45B), while TG Therapeutics Inc trades at $55 (market cap $8.16B). The key difference: TG Therapeutics Inc is far larger — about 5.6× Direxion NASDAQ 100 Equal Weighted Index Shares's market cap, and Direxion NASDAQ 100 Equal Weighted Index Shares is more actively traded (323,568 versus 1,735,121). Which is the better fit depends on your goals — on Pluang, investors hold Direxion NASDAQ 100 Equal Weighted Index Shares for 48 Days and TG Therapeutics Inc for 16 Days on average.
| QQQE | TGTX | |
|---|---|---|
Market Cap | $1.45B | $8.16B |
Volume | 323,568 | 1,735,121 |
Sector | Broad Market / Factor | Health |
52-Week High | $124.69 | $59.06 |
52-Week Low | $96.06 | $26.94 |
Typical Hold Time | 48 Days | 16 Days |
Enterprise Value | — | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QQQE, the Direxion NASDAQ-100 Equal Weighted Index ETF, trades at $121.68, down 0.17% on the day. Technical indicators show a bullish trend with moving averages supporting upside momentum, while oscillators are neutral. The equal-weight strategy reduces technology concentration compared to the standard NASDAQ-100 ETF, offering diversified exposure to large-cap growth stocks. Recent news highlights tactical preference for QQQE over QQQ due to its fundamental and technical positioning.
The outlook for QQQE is positive, driven by its equal-weight approach mitigating single-stock risk and capturing broad Nasdaq growth. Key risks include market volatility and sector concentration shifts. Investment appeal lies in its structural diversification, though reliance on tech sector performance remains a factor for investors to weigh.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Direxion NASDAQ 100 Equal Weighted Index Shares
QQQE is an ETF that seeks to track the performance of the NASDAQ-100 Equal Weighted Index. Unlike traditional market-capitalization-weighted indexes, this fund assigns equal weight to each of the 100 non-financial companies in the NASDAQ-100 and rebalances quarterly. This equal-weighting scheme reduces concentration risk in the largest technology companies and increases the fund's exposure to smaller-cap and mid-cap companies within the index, providing a differentiated growth profile.
Read more on QQQE →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
